1-4 of 4
Viet Q. Ho, PharmD, RPh, BCOP
Close
Sort by
Journal Articles

Treatment-Related Morbidity and Mortality Associated with Remission Induction in Adolescent and Young Adult (AYA) Versus Young Adult Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Cory Michael Vela, PharmD, Viet Q. Ho, PharmD, RPh, BCOP, Justina Ofori Frimpong, PharmD, BCOP, Bryan Brinda, Pharm.D., Timothy George, Pharm.D., BCOP, Kendra L. Sweet, MD, Eric Padron, MD, David Sallman, MD, Alan F List, MD, Jeffrey E. Lancet, MD, Rami S. Komrokji, MD
Journal: Blood
Blood (2016) 128 (22): 5167.
https://doi.org/10.1182/blood.V128.22.5167.5167
Published: 2016
Journal Articles

Transition of Intensive Chemotherapy for Acute Lymphoblastic Leukemia (ALL) to the Outpatient Setting: Analysis of Safety and Cost Savings

Timothy E. Kubal, MD MBA, Christopher Rodriguez Salamanca, PA, Julio C Chavez, MD, Bijal D. Shah, MD, Rami S. Komrokji, MD, Viet Q. Ho, PharmD, RPh, BCOP, Jeffrey E Lancet, MD
Journal: Blood
Blood (2015) 126 (23): 5604.
https://doi.org/10.1182/blood.V126.23.5604.5604
Published: 2015
Journal Articles

Inferior Outcomes with Intensive AML Induction Therapy in Patients Age 70 or Greater Compared to Age 60-69

Bryan Brinda, Pharm.D., Viet Q. Ho, PharmD, RPh, BCOP, Timothy George, Pharm.D., BCOP, Jeffrey E Lancet, MD, Rami S. Komrokji, MD
Journal: Blood
Blood (2015) 126 (23): 3750.
https://doi.org/10.1182/blood.V126.23.3750.3750
Published: 2015
Journal Articles

Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia after Ibrutinib Discontinuation Outside Clinical Trials: A Single Institution Experience

Jose D Sandoval-Sus, MD, Julio C Chavez, MD, Samir Dalia, MD, Celeste M. Bello, MD, Bijal D. Shah, MD, Viet Q. Ho, PharmD, RPh, BCOP, Lisa Nodzon, PhDANP, Mohamed A. Kharfan-Dabaja, MD, Eduardo M. Sotomayor, MD, Lubomir Sokol, MD PhD, Javier Pinilla-Ibarz
Journal: Blood
Blood (2015) 126 (23): 2945.
https://doi.org/10.1182/blood.V126.23.2945.2945
Published: 2015